Bradykinin B2 receptors increase hippocampal excitability and susceptibility to seizures in mice

Neuroscience

Volumn 248, Issue , 2013, Pages 392-402

  Rodi, D ^a,b   Buzzi, A ^a   Barbieri, M ^a   Zucchini, S ^a,b,c   Verlengia, G ^a,b   Binaschi, A ^a,b   Regoli, D ^a,b   Boschi, A ^a   Ongali, B ^d   Couture, R ^d   Simonato, M ^a,b,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b National Institute of Neuroscience   (Italy)

^c Laboratorio per le Tecnologie delle Terapie Avanzate   (Italy)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Autoradiography; Electrophysiology; Epilepsy; Kainate; Kindling

Indexed keywords

BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; KAINIC ACID; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; EPILEPTOGENESIS; HIPPOCAMPUS; KNOCKOUT MOUSE; LIMBIC CORTEX; MALE; MOUSE; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRIFORM CORTEX; SEIZURE SUSCEPTIBILITY; WILD TYPE; ANIMAL; CHEMICALLY INDUCED; DEFICIENCY; DISEASE PREDISPOSITION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOPHYSIOLOGY; SEIZURE;

ANIMALS; BRADYKININ; BRADYKININ B1 RECEPTOR ANTAGONISTS; BRADYKININ B2 RECEPTOR ANTAGONISTS; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; HIPPOCAMPUS; KAINIC ACID; MICE; MICE, KNOCKOUT; PIRIFORM CORTEX; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; SEIZURES;

EID: 84880956973     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.06.038     Document Type: Article

References (52)

1. Andersen P., Bliss T.V.P., Skrede K.K. Unit analysis of the hippocampal population spike. Exp Brain Res 1971, 13:208-221.
2. Anderson W.W., Lewis D.V., Swartzwelder H.S., Wilson W.A. Magnesium-free medium activates seizure-like events in the rat hippocampal slice. Brain Res 1986, 398:215-219.
3. Anderson W.W., Collingridge G.L. The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J Neurosci Methods 2001, 108:71-83.
4. Argañaraz G.A., Perosa S.R., Lencioni E.C., Bader M., Cavalheiro E.A., da Graça Naffah-Mazzacoratti M., Pesquero J.B., Silva J.A. Role of kinin B1 and B2 receptors in the development of pilocarpine model of epilepsy. Brain Res 2004, 1013:30-39.
5. Argañaraz G.A., Silva J.A., Perosa S.R., Pessoa L.G., Carvalho F.F., Bascands J.L., Bader M., da Silva Trindade E., Amado D., Cavalheiro E.A., Pesquero J.B., da Graça Naffah-Mazzacoratti M. The synthesis and distribution of the kinin B1 and B2 receptors are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy. Brain Res 2004, 1006:114-125.
6. Borkowski J., Ramsom R., Seabrook G., Trumbauer M., Chen H., Hill R. Target disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 1995, 270:13706-13710.
7. Bregola G., Varani K., Gessi S., Beani L., Bianchi C., Borea P.A., Regoli D., Simonato M. Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy. Neuroscience 1999, 92:1043-1049.
8. Bregola G., Zucchini S., Rodi D., Binaschi A., D'Addario C., Landuzzi D., Reinscheid R., Candeletti S., Romualdi P., Simonato M. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures. J Neurosci 2002, 22:10030-10038.
9. Calixto J.B., Medeiros R., Fernandes E.S., Ferreira J., Cabrini D.A., Campos M.M. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004, 143:803-818.
10. Cloutier F., de Sousa Buck H., Ongali B., Couture R. Pharmacologic and autoradiographic evidence for an up-regulation of kinin B(2) receptors in the spinal cord of spontaneously hypertensive rats. Br J Pharmacol 2002, 135:1641-1654.
11. Costa-Neto C.M., Dillenburg-Pilla P., Heinrich T.A., Parreiras-e-Silva L.T., Pereira M.G., Reis R.I., Souza P.P. Participation of kallikrein-kinin system in different pathologies. Int Immunopharmacol 2008, 8:135-142.
12. Delmas P., Wanaverbecq N., Abogadie F.C., Mistry M., Brown D.A. Signaling microdomains define the specificity of receptor-mediated InsP(3) pathways in neurons. Neuron 2002, 34:209-220.
13. Duka A., Kintsurashvili E., Duka I., Ona D., Hopkins T.A., Bader M., Gavras I., Gavras H. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 2008, 51:1352-1357.
14. Gröger M., Lebesgue D., Pruneau D., Relton J., Kim S.W., Nussberger J., Plesnila N. Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005, 25:978-989.
15. Hellal F., Pruneau D., Palmier B., Faye P., Croci N., Plotkine M., Marchand-Verrecchia C. Detrimental role of bradykinin B2 receptor in a murine model of diffuse brain injury. J Neurotrauma 2003, 20:841-851.
16. Hock F.J., Wirth K., Albus U., Linz W., Gerhards H.J., Wiemer G., Henke S., Breipohl G., König W., Knolle J., Schölkens B.A. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991, 102:769-773.
17. Hösli L., Hösli E., Kaeser H., Lefkovits M. Colocalization of receptors for vasoactive peptides on astrocytes of cultured rat spinal cord and brain stem: electrophysiological effects of atrial and brain natriuretic peptide, neuropeptide Y and bradykinin. Neurosci Lett 1992, 148:114-116.
18. Hunter W.M., Greenwood F.C. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 1962, 194:495-496.
19. Janumpalli S., Butler L.S., MacMillan L.B., Limbird L.E., McNamara J.O. A point mutation (D79N) of the alpha2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. J. Neurosci 1998, 18:2004-2008.
20. Korn S.J., Giacchino J.L., Chamberlin N.L., Dingledine R. Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA-mediated inhibition. J Neurophysiol 1987, 57:325-341.
21. Lacoste B., Tong X.K., Lahjouji K., Couture R., Hamel E. Cognitive and cerebrovascular improvements following kinin B1 receptor blockade in Alzheimer's disease mice. J Neuroinflammation 2013, 10:57.
22. Liu H.T., Akita T., Shimizu T., Sabirov R.Z., Okada Y. Bradykinin-induced astrocyte-neuron signalling: glutamate release is mediated by ROS-activated volume-sensitive outwardly rectifying anion channels. J Physiol 2009, 587:2197-2209.
23. Mazzuferi M., Binaschi A., Rodi D., Mantovani S., Simonato M. Induction of B1 bradykinin receptors in the kindled hippocampus increases extracellular glutamate levels: a microdialysis study. Neuroscience 2005, 135:979-986.
24. Mody I., Lambert J.D., Heinemann U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J Neurophysiol 1987, 57:869-888.
25. Noda M., Kariura Y., Amano T., Manago Y., Nishikawa K., Aoki S., Wada K. Expression and function of bradykinin receptors in microglia. Life Sci 2003, 72:1573-1581.
26. Ongali B., Campos M.M., Bregola G., Rodi D., Regoli D., Thibault G., Simonato M., Couture R. Autoradiographic analysis of the rat brain kinin B1 and B2 receptors: normal distribution and alterations induced by epilepsy. J Comp Neurol 2003, 461:506-519.
27. Ongali B., Hellal F., Rodi D., Plotkine M., Marchand-Verrecchia C., Pruneau D., Couture R. Autoradiographic analysis of mouse brain kinin B1 and B2 receptors after closed head trauma and ability of Anatibant mesylate to cross the blood-brain barrier. J Neurotrauma 2006, 23:696-707.
28. Paxinos G., Franklin K. The mouse brain in stereotaxic coordinates 2001, Academic Press, New York. 2nd ed.
29. Parpura V., Basarsky T.A., Liu F., Jeftinija K., Jeftinija S., Haydon P.G. Glutamate-mediated astrocyte-neuron signalling. Nature 1994, 369:744-747.
30. Pereira M.G., Gitaí D.L., Paçó-Larson M.L., Pesquero J.B., Garcia-Cairasco N., Costa-Neto C.M. Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy. Int Immunopharmacol 2008, 8:200-205.
31. Perosa S.R., Argañaraz G.A., Goto E.M., Costa L.G., Konno A.C., Varella P.P., Santiago J.F., Pesquero J.B., Canzian M., Amado D., Yacubian E.M., Carrete H., Centeno R.S., Cavalheiro E.A., Silva J.A., da Graça Naffah-Mazzacoratti M. Kinin B1 and B2 receptors are overexpressed in the hippocampus of humans with temporal lobe epilepsy. Hippocampus 2007, 17:26-33.
32. Pesquero J.B., Pesquero J.L., Oliveira S.M., Roscher A.A., Metzger R., Ganten D., Bader M. Molecular cloning and functional characterization of a mouse bradykinin B1 receptor gene. Biochem Biophys Res Commun 1996, 220:219-225.
33. Pesquero J.B., Araujo R.C., Heppenstall P.A., Stucky C.L., Silva J.A., Walther T., Oliveira S.M., Pesquero J.L., Paiva A.C., Calixto J.B., Lewin G.R., Bader M. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000, 97:8140-8145.
34. Pitkänen A., Sutula T.P. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. Lancet Neurol 2002, 1:173-181.
35. Pitkänen A., Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011, 10:173-186.
36. Pruneau D., Chorny I., Benkovitz V., Artru A., Roitblat L., Shapira Y. Effect of LF 16-0687MS, a new nonpeptide bradykinin B2 receptor antagonist, in a rat model of closed head trauma. J Neurotrauma 1999, 16:1057-1065.
37. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
38. Raidoo D.M., Ramsaroop R., Naidoo S., Müller-Esterl W., Bhoola K.D. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology 1997, 36:153-160.
39. Relton J.K., Beckey V.E., Hanson W.L., Whalley E.T. CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke 1997, 28:1430-1436.
40. Rodi D., Couture R., Ongali B., Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr Pharm Des 2005, 11:1313-1326.
41. Seguin T.H., Buleon M., Destrube M., Ranera M.T., Couture R., Girolami J.P., Tack I. Hemodynamic and renal involvement of B1 and B2 kinin receptors during the acute phase of endotoxin shock in mice. Int Immunopharmacol 2008, 8:217-221.
42. Silva J.A., Goto E.M., Perosa S.M., Argañaraz G.A., Cavalheiro E.A., Naffah-Mazzacoratti M.G., Pesquero J.B. Kinin B1 receptors facilitate the development of temporal lobe epilepsy in mice. Int Immunopharmacol 2008, 8:197-199.
43. Stephens G.J., Marriott D.R., Djamgoz M.B., Wilkin G.P. Electrophysiological and biochemical evidence for bradykinin receptors on cultured rat cortical oligodendrocytes. Neurosci Lett 1993, 153:223-226.
44. Talbot S., Couture R. Emerging role of microglial kinin B1 receptor in diabetic pain neuropathy. Exp Neurol 2012, 234:373-381.
45. Thornton E., Ziebell J.M., Leonard A.V., Vink R. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury. Molecules 2010, 15:6598-6618.
46. Trabold R., Erös C., Zweckberger K., Relton J., Beck H., Nussberger J., Müller-Esterl W., Bader M., Whalley E., Plesnila N. The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010, 30:130-139.
47. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46:1724-1743.
48. Viel T.A., Buck H.S. Kallikrein-kinin system mediated inflammation in Alzheimer's disease in vivo. Curr Alzheimer Res 2011, 8:59-66.
49. Wahl M., Young A.R., Edvinsson L., Wagner F. Effects of kininase II inhibitors on the vasomotor response to bradykinin of feline intracranial and extracranial arteries in vitro and in situ. J Cereb Blood Flow Metab 1983, 3:339-345.
50. Wirth K., Breipohl G., Stechl J., Knolle J., Henke S., Schölkens B. DesArg9-D-Arg[Hyp3, Thi5, D-Tic7, Oic8]bradykinin (desArg10-[Hoe140]) is a potent bradykinin B1 receptor antagonist. Eur J Pharmacol 1991, 205:217-218.
51. Xiao H.D., Fuchs S., Cole J.M., Disher K.M., Sutliff R.L., Bernstein K.E. Regulation of cardiovascular signaling by kinins and products of similar converting-enzyme systems. Am J Physiol Heart Circ Physiol 2003, 284:H1969-H1977.
52. Zucchini S., Buzzi A., Barbieri M., Rodi D., Paradiso B., Binaschi A., Coffin J.D., Marzola A., Cifelli P., Belluzzi O., Simonato M. FGF-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss. J Neurosci 2008, 28:13112-13124.